Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Somaliland denies trading recognition with Israel for accepting Gazans - 2Turkey, Egypt, Qatar discuss second phase of Gaza ceasefire deal
- 3Exploring the Difficulties of Beginning a Family: Individual Experiences
- 45 Eating routine Well disposed Snacks to Keep You Fulfilled
- 5This St Nick Truly Can Advise How To Drink And Hack Your Headache
- German official report: Teen social media ban faces legal hurdles
- Israeli strike on Gaza City vehicle kills at least four, report says
- Find Successful Magnificence Items for Sparkling Skin
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Holiday spots Well known With Americans In 2024
- Monetary Security: Building Serious areas of strength for an Establishment
- How did life begin on Earth? New experiments support 'RNA world' hypothesis
- Climate change is straining Alaska's Arctic. A new mining road may push the region past the brink
- Rescuers give up hope for the humpback whale stranded in the Baltic Sea
